Results 131 to 140 of about 952 (211)

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Genki Sato, Hiroshi Uchino, Takahisa Hirose   +7 more
wiley   +1 more source

The miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu, Yu Fang, Meirong Xu, Zuopeng Lu, Yu Cao, Yana Gao   +5 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading

Acta Dermato-Venereologica, 2018
Hiroyuki Takama, Makiko Yoshida, Kentaro Izumi, Takeshi Yanagishita, Jun Muto, Yuichiro Ohshima, Wataru Nishie, Hiroshi Shimizu, Masashi Akiyama, Daisuke Watanabe   +9 more
doaj   +1 more source

Diagnostic performance of SD‐ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy

Journal of Diabetes Investigation, EarlyView.
Study population, methodology and key findings of the study. ABSTRACT Aims This study aimed to evaluate the clinical efficacy of SD‐ΔRR as a novel methodology for short‐duration heart rate variability (HRV) assessment for the diagnosis of diabetic sensorimotor polyneuropathy (DSPN) in patients with diabetes.
Katsuyoshi Katayama, Haruhito A. Uchida, Toshihiko Nagao, Jun Eguchi, Kenji Tsuji, Yoshinori Matsumoto, Ichiro Nojima, Keiko Tanaka, Hidemi Takeuchi, Yasuhiro Onishi, Rika Takemoto, Satoshi Miyamoto, Kenichi Shikata, Jun Wada   +13 more
wiley   +1 more source

Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Journal of Diabetes Investigation, EarlyView.
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo, Tetsuro Kobayashi, Kyoichiro Tsuchiya   +4 more
wiley   +1 more source

Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients

Journal of Diabetes Investigation, EarlyView.
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda, Yosuke Okada, Tomoya Mita, Keiichi Torimoto, Kenichi Tanaka, Fumiya Sato, Naoto Katakami, Hidenori Yoshii, Keiko Nishida, Shingo Nakayamada, Ryota Ishii, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada   +13 more
wiley   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, EarlyView.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source

Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

Journal of Diabetes Investigation, EarlyView.
We conducted the single‐center, retrospective cohort study to evaluate and compare the risk of diabetic eye and kidney complications between newly initiated once‐daily liraglutide (0.9 mg) and once‐weekly dulaglutide (0.75 mg) in 331 Japanese patients with type 2 diabetes.
Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami   +4 more
wiley   +1 more source

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, EarlyView.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source